ZYNERBA PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense
ZYNERBA PHARMACEUTICALS, INC. reported Share-based Payment Arrangement, Expense of $5.18 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2021-03-10
- ZYNERBA PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2016-12-31 was $887.42K, a 16.19% increase year-over-year.
- ZYNERBA PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2016-09-30 was $805.40K, a 3.75% decline year-over-year.
- ZYNERBA PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2016-06-30 was $812.74K.
- ZYNERBA PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2016-03-31 was $763.80K.
- ZYNERBA PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2020 was $5.18M, a 6.91% decline from fiscal 2019.
- ZYNERBA PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2019 was $5.56M, a 16.06% decline from fiscal 2018.
- ZYNERBA PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2018 was $6.63M, a 17.34% increase from fiscal 2017.
- ZYNERBA PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2017 was $5.65M, a 72.72% increase from fiscal 2016.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2020-12-31 | $5.18M 10-K · filed 2021-03-10 | |||
| 2019-12-31 | $5.56M 10-K · filed 2021-03-10 | |||
| 2018-12-31 | $6.63M 10-K · filed 2021-03-10 | |||
| 2017-12-31 | $5.65M 10-K · filed 2020-03-10 | |||
| 2016-12-31 | $887.42K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-11 | $1.69M derived: sum of 2 quarters · filed 2019-03-11 | $2.51M derived: sum of 3 quarters · filed 2019-03-11 | $3.27M 10-K · filed 2019-03-11 |
| 2016-09-30 | $805.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $1.62M derived: sum of 2 quarters · filed 2016-11-14 | $2.38M 10-Q · filed 2016-11-14 | $3.15M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $812.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $1.58M 10-Q · filed 2016-08-11 | $2.34M derived: sum of 3 quarters · filed 2018-03-12 | $3.18M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-03-31 | $763.80K 10-Q · filed 2016-05-12 | $1.53M derived: sum of 2 quarters · filed 2018-03-12 | $2.36M derived: sum of 3 quarters · filed 2018-03-12 | |
| 2015-12-31 | $763.80K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $1.60M derived: sum of 2 quarters · filed 2018-03-12 | $1.60M 10-K · filed 2018-03-12 | |
| 2015-09-30 | $836.82K 10-Q · filed 2015-11-12 | $836.82K 10-Q · filed 2016-11-14 |